Ezetimibe

ATLANTA — Obicetrapib, a novel cholesteryl ester transfer protein inhibitor, reduced atherogenic lipoprotein particles alone or in combination with ezetimibe, according to new data from the ROSE2 trial.

ATLANTA — An investigational monthly PCSK9 inhibitor cut LDL cholesterol by more than 50% at 1 year among adults with CVD or with very high risk, in addition to background statin and ezetimibe therapy, researchers reported.

Esperion Therapeutics announced the FDA approved broad label expansion for bempedoic acid and bempedoic acid/ezetimibe for CV risk reduction and LDL lowering in both primary and secondary prevention populations.

Esperion announced the FDA granted an updated indication for bempedoic acid and bempedoic acid plus ezetimibe for the treatment of primary hyperlipidemia in eligible patients with genetic hyperlipidemia or atherosclerotic CVD.

Researchers observed no increased risk for new-onset diabetes among IMPROVE-IT participants assigned to ezetimibe plus statin therapy vs. statin monotherapy, according to a research letter.

In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial.

Long-term adherence to PCSK9 inhibition was high among a high-risk cohort with familial hypercholesterolemia, which improved LDL goal attainment when added on top of background statin therapy and ezetimibe, researchers reported.